FDA clears Nordisk’s Victoza as only Type II diabetes drug to cut cardio risks

The FDA approved a new indication for Novo Nordisk‘s (NYSE:NVO) Victoza liraglutide injection, clearing it as the only Type II diabetes medication indicated to reduce the risk of cardiovascular diseases, like heart attack and stroke.

The regulatory watchdog’s decision is based on results from Nordisk’s 9,300-patient Leader trial, which showed that Victoza significantly reduced the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA clears Nordisk’s Victoza as only Type II diabetes drug to cut cardio risks appeared first on MassDevice.

from MassDevice http://ift.tt/2xjx1x4